Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

300.83 (USD) • At close June 6, 2025
Bedrijfsnaam Alnylam Pharmaceuticals, Inc.
Symbool ALNY
Munteenheid USD
Prijs 300.83
Beurswaarde 39,224,622,040
Dividendpercentage 0%
52-weken bereik 147.25 - 310
Industrie Biotechnology
Sector Healthcare
CEO Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB
Website https://www.alnylam.com

An error occurred while fetching data.

Over Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex

Vergelijkbare Aandelen

Insulet Corporation logo

Insulet Corporation

PODD

311.77 USD

BioMarin Pharmaceutical Inc. logo

BioMarin Pharmaceutical Inc.

BMRN

56.65 USD

Viatris Inc. logo

Viatris Inc.

VTRS

8.71 USD

Bio-Techne Corporation logo

Bio-Techne Corporation

TECH

48.69 USD

Incyte Corporation logo

Incyte Corporation

INCY

68.77 USD

ICON Public Limited Company logo

ICON Public Limited Company

ICLR

139.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)